Breast cancer Page
[…] PDX models are created by transplanting human tumour tissue into immunodeficient mice. Our collection of breast cancer PDX models includes those from patients affected by the most advanced and lethal forms of […]
Bridging the translational gap: How PDX models are transforming breast cancer research, drug discovery and precision oncology Blog Post
[…] her own laboratory at the University of Utah’s Huntsman Cancer Institute and began developing novel breast cancer PDX models. These spanned different breast cancer types. Her research focuses on solving the problem […]
HCI-016 breast cancer PDX Product
HCI-016 PDX: Sample collected in 2013 from breast tumour of Caucasian female, age 93 at time of collection with a primary diagnosis of IDC;2013.
HCI-008 breast cancer PDX Product
HCI-008 PDX: Sample collected from pleural effusion of Caucasian female, age 87 with a primary diagnosis of inflammatory breast cancer (2007).
HCI-049 breast cancer PDX Product
HCI-049 PDX: Human breast cancer-derived xenograft retains high fidelity to original tumour. Valuable resources for drug discovery and precision oncology.
HCI-025 breast cancer PDX Product
HCI-025 PDX: Human breast cancer-derived xenograft retains high fidelity to original tumour. Valuable resources for drug discovery and precision oncology.
HCI-027 breast cancer PDX Product
HCI-027 PDX: Human breast cancer-derived xenograft retaining high fidelity to original tumour. Valuable resources for drug discovery and precision oncology.
HCI-028 breast cancer PDX Product
HCI-028 PDX: One of many Patient Derived Xenografts providing breast cancer models including endocrine-resistant estrogen receptor-positive (ER+).
HCI-019 breast cancer PDX Product
HCI-019 PDX: Human breast cancer-derived xenograft retains high fidelity to original tumour. Valuable resources for drug discovery and precision oncology.
HCI-017 breast cancer PDX Product
HCI-017 PDX: One of many Patient Derived Xenografts providing models for breast cancer including drug-resistant, metastatic tumours, and HER2+ tumours.
